Bumblebees were subjected to 5 day exposure to Imidacloprid and/or/none twice daily 670 nm. by Michael Barry Powner (11337243)

“…As with respiration we then asked what 670nm duration was needed for correction B. Bumblebees (≥ 20 bees per group) maintained on Imidacloprid were exposed to 670nm light for 0.5, 1, 5, 15 or 60mins. …”

Bland-Altman type plots of intersession difference. by C. Vijay Reena Durai (14498259)

Subjects:

S1 File - by C. Vijay Reena Durai (14498259)

Subjects:

Fig 1 - by C. Vijay Reena Durai (14498259)

Subjects:

Binocular summation ratio. by C. Vijay Reena Durai (14498259)

Subjects:

Two Microsoft excel spreadsheets containing the raw data of the study have been added as supporting information. by C. Vijay Reena Durai (14498259)

Subjects:

Representation of better of the two eyes’ monocular FMTs and binocular FMTs. by C. Vijay Reena Durai (14498259)

Subjects:

Representation of better of the two eyes’ monocular FMTs and binocular FMTs. by C. Vijay Reena Durai (14498259)

Subjects:

Cytosolic mitochondrial DNA release upon MeV and MeV-ΔV infection in culture and in mice. by Pierre Khalfi (7868252)

<i>Gnas</i> deletion in hypothalamic <i>Opn5</i> neurons. by Kevin D. Gaitonde (15411707)

Subjects:

Comparison of the decrease of CFU in CSF and blood between treatment groups within the first 6 h after treatment. by Luca G. Valente (12463057)

Design and Synthesis of Novel sEH Inhibitors for the Treatment of Inflammatory Bowel Disease by Huashen Xu (13987046)

“…Especially, lead compounds <b>A1</b> and <b>A9</b> showed potent inhibitory activities against sEH (<b>A1</b> and <b>A9</b>; hsEH IC₅₀ = 0.1 nM, msEH IC₅₀ = 0.1 nM). …”

Design and Synthesis of Novel sEH Inhibitors for the Treatment of Inflammatory Bowel Disease by Huashen Xu (13987046)

“…Especially, lead compounds <b>A1</b> and <b>A9</b> showed potent inhibitory activities against sEH (<b>A1</b> and <b>A9</b>; hsEH IC₅₀ = 0.1 nM, msEH IC₅₀ = 0.1 nM). …”

Design and Synthesis of Novel sEH Inhibitors for the Treatment of Inflammatory Bowel Disease by Huashen Xu (13987046)

“…Especially, lead compounds <b>A1</b> and <b>A9</b> showed potent inhibitory activities against sEH (<b>A1</b> and <b>A9</b>; hsEH IC₅₀ = 0.1 nM, msEH IC₅₀ = 0.1 nM). …”

Design and Synthesis of Novel sEH Inhibitors for the Treatment of Inflammatory Bowel Disease by Huashen Xu (13987046)

“…Especially, lead compounds <b>A1</b> and <b>A9</b> showed potent inhibitory activities against sEH (<b>A1</b> and <b>A9</b>; hsEH IC₅₀ = 0.1 nM, msEH IC₅₀ = 0.1 nM). …”

Fig 5 - by Héctor Raúl Olivares-Sánchez (13014866)

Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…Mean outpatient visits in the recurrence group decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …”

MBIC50 and MBEC50 values (µg/mL) of synthesized 1,2,3,5-tetrazine derivatives against bacteria pathogen strains. by Jean Paul Dzoyem (6424445)

Subjects:

Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

“…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

“…Outpatient visit frequency also significantly declined from 11.5 ± 4.3 visits in the year before surgery to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal-Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g004" target="_blank">Fig 4</a>).…”